Kornimate/medical-research-clean huggingface dataset:
feasibility study of prostate tumor localization for focal cryoablation of prostate carcinoma

Conditions: Prostate Cancer

Summary: the purpose of the present study is to find out if mri techniques examining (1) the motion of water molecules in the prostate (diffusion sensitive mri), (2) the difference in blood flow to the prostate (dynamic contrast enhanced mri), and (3) differences in chemical composition of the prostate (mr spectroscopy), can be used to detect prostate cancer early and non-invasively. localization of the cancer within the prostate would be of particular importance in focal cryoablation of prostate carcinoma which we hope to improve as a result of this project. additional aim of the study is to correlate expression of genes believed to pay a role in prostate cancer with mri findings.

radical prostatectomy patients will undergo an mri prior to their scheduled surgery. ex vivo imaging will be done on prostates once removed. results from the final pathology with be compared with results of imaging to determine the accuracy of the image analysis in cancer localization and staging. brachytherapy patients will undergo an mri prior to their scheduled procedure. two areas of suspected cancer and two areas without suspected cancer will be prospectively identified based on the mri imaging. at the time of brachytherapy, transrectal needle biopsies will be obtained from the previously identified areas. the needle cores will be reviewed by study pathologist to determine the accuracy of the image analysis in cancer localization and staging.

Eligibility criteria:
inclusion criteria: * patients who have been diagnosed with prostate cancer and are scheduled for radical prostatectomy or for brachytherapy * patients who have not received any preoperative treatment for their diagnosis of prostate cancer exclusion criteria: * patients with implants that are electronically, magnetically, or mechanically active * patients with intracranial aneurysm clips * patients who have undergone cosmetic eyelid surgery * patients with history of pheochromocytoma, insulinoma and acute glaucoma * patients with estimated glomerular filtration rate (egfr) less than 60 ml/min/1.73m2

Keywords: prostate cancer dynamic contrast enhanced mri non-invasive prostate cancer detection
blood salvage from liver donors: a feasibility pilot study

Conditions: Liver Transplantation; Erythrocyte Transfusion

Summary: blood recovery is a common procedure that limits patient exposure to allogeneic blood products. blood recovery is usually performed during different types of surgery, including cardiac and vascular surgery, or liver transplantation. basically, the process utilizes blood cell savers and cell separators and is finalized to auto-transfusion. in our hospital, the blood recovery is carried out with the catsmart continuous-flow device (fresenius kabi ag, bad homburg, germany) that warrants the removal of \> 95% of heparin, potassium, free hemoglobin, and non-emulsifiable lipids. in liver transplantation (lt), before removing the organ from the donor, the blood is usually flushed out of the liver. nonetheless, in some circumstances, donor blood cells may be transferred to recipients together with the solid organ during graft implantation. this is a feasibility study exploring rbc (red blood cell) concentrates obtained from the blood organ donor to support transfusion requirements in liver recipients. donor rbc units are produced according to the quality standards recommended by the european directorate for the quality of medicines \& healthcare of the council of europe, with equivalent content of hb and residual leukocytes as standard rbc products.


Eligibility criteria:
inclusion criteria: * all adult patients (≥ 18 years) receiving a liver transplant from deceased donors at fondazione policlinico a. gemelli irccs are eligible for the study. * liver procurement at fondazione policlinico a. gemelli irccs. * identical abo group in donor and recipient. * signed written informed consent to study participation. exclusion criteria: * age \<18 y.o. * d-negative recipient with d-positive donor. * cytomegalovirus-negative recipient and cytomegalovirus -positive donor. * refusal to sign written informed consent to study participation.
remdesivir- ivermectin combination therapy in severe covid-19

Conditions: Covid19

Summary: recent study reported in vitro synergistic interaction between two fda approved drugs, remdesivir (rdv) and ivermectin (ivm) resulting in enhanced antiviral activity against sars-cov-2, the causative pathogen of covid-19. the aim of the current study is comparing the efficacy and safety of combining remdesivir and ivermectin versus using remdesivir alone in patients with severe covid-19.


Eligibility criteria:
inclusion criteria: * adult, hospitalized severe covid-19 patients; both genders; given informed consent (covid-19 infection confirmed by pcr, severe illness is defined as patients with spo2 ≤94% on room air, including patients on supplemental oxygen). exclusion criteria: * patients under 18 years old, pregnant ladies, advanced renal diseases (cr. clearance \ 3 folds of normal, arrhythmia.
electric toothbrush efficacy in preventing dental plaque development

Conditions: Dental Plaque; Calculus, Dental

Summary: the present study will be the first to compared dental plaque quantitation between an oscillating-rotating electric toothbrush and a manual toothbrush with a new qlf technology.

this is a randomized controlled trial of 12-weeks duration designed to assess whether a new commercially available oscillating-rotating electric toothbrush can objectively improve dental plaque parameters obtained via light induced fluorescence (qlf) technology. the study will be conducted in a dental clinic in italy

Eligibility criteria:
inclusion criteria: * healthy adult (aged 18-50 years) * non-smokers * without clinical signs of periodontitis with at least 10 natural anterior teeth in total (cuspid to cuspid and lower and upper jaw). exclusion criteria: * significant oral soft tissue pathology or any type of gingival overgrowth other than plaque-induced gingivitis, * with fixed and removable orthodontic appliances or removable dentures, * with any other medical condition that, in the opinion of the principal investigator, would jeopardize the participant's safety or diminish the validity of study results
efficacy of intravenous iron therapy in maintaining hemoglobin concentration on patients undergoing bimaxillary orthognathic surgery

Conditions: Facial Asymmetry; Retrognathism; Prognathism

Summary: the aim of this study is to evaluate the effect of intravenous iron isomaltoside on maintaining hemoglobin concentration in patients undergoing bimaxillary orthognathic surgery. fifty-eight patients, aged 19 to 40 years, scheduled for bimaxillary orthognathic surgery will be divided into monofer (n=29) and control (n=29) groups. randomly selected patients of the ulinastatin group are given intravenous iron isomaltoside. in contrast, patients in the control group receive an equivalent volume of normal saline as a placebo. the primary endpoints are postoperative hemoglobin concentration.

bimaxillary orthognathic surgery is widely used to correct dentofacial anomaly and bimaxillary prognathism. however, the complicated vascularity of the surgical site and limited visual field can lead to unexpected bleeding. intravenous iron isomaltoside 1000 (monofer®) significantly increased the hemoglobin level and prevented anemia 4 weeks after cardiac surgery. the aim of this study is to evaluate the effect of intravenous iron isomaltoside on maintaining hemoglobin concentration in patients undergoing bimaxillary orthognathic surgery. fifty-eight patients, aged 19 to 40 years, scheduled for bimaxillary orthognathic surgery will be divided into monofer (n=29) and control (n=29) groups. randomly selected patients of the ulinastatin group are given intravenous iron isomaltoside. in contrast, patients in the control group receive an equivalent volume of normal saline as a placebo. the primary endpoints are postoperative hemoglobin concentration.

Eligibility criteria:
inclusion criteria: * patients who are scheduled to undergo bimaxillary orthognathic surgery * american society of anesthesiologists (asa) physical status i-ii exclusion criteria: * hematologic disease * renal-related anemia * hepatitis * pregnancy * hypersensitivity to iron * severe atopic disease * allergic to drugs
evaluation of the timing of the nebulization related to the physiotherapy session

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to determine the optimal time for the nebulization depending on the respiratory physiotherapy session in cystic fibrosis patients.


Eligibility criteria:
inclusion criteria: * stable cystic fibrosis patients older than 16 y.o. * pseudomonas aeruginosa colonization * hypersecretion exclusion criteria: * kidney failure * no pregnancy
role of txa in patients undergoing breast free flap reconstruction

Conditions: Breast Cancer; Blood Loss, Surgical

Summary: tranexamic acid (txa) is a synthetic, competitive lysine receptor inhibitor on plasminogen. it ultimately stabilizes the fibrin matrix, therefore used as a hemostatic agent for various indications. while there has been indications for orthopedic and trauma surgery, there is no clear data for its role in patients who are undergoing free tissue transfer. studies have shown that patients undergoing free tissue transfer can have transfusion rates ranging from 7.2% to 34.9%, which data also showing association between transfusion requirement and higher free flap failure rate. there has been a few retrospective studies that evaluated the effect of txa in free tissue transfer and the results showed no increased risk of microanastomosis failure but some showing decreased blood loss. this study aims to further analyze the role of txa in patients undergoing breast free flap reconstruction with randomized, prospective trial. control group will not receive txa while experimental group will receive txa. both groups will receive standard of care breast free flap surgery as well as post-op care, which is streamlined with early recovery after surgery (eras) protocol. their pre and post-op hemoglobin will be compared, as well as rates of transfusion, surgical outcome and surgical complications including hematoma, flap failure, and any other medical complications such as deep vein thrombosis (dvt)/ pulmonary embolism (pe).


Eligibility criteria:
inclusion criteria: * all female patients who are 18 years or older who will undergo unilateral or bilateral abdomen-based free flap breast reconstruction at uva medical center exclusion criteria: * subjects with ages \<18 years * allergy to txa * subjects who has contraindications to txa: anyone who has active intravascular thrombosis or anyone with subarachnoid hemorrhage * subjects who have anemia (defined as baseline hemoglobin \<8 g/dl * subjects who cannot read or understand english * subjects who are pregnant

Keywords: autologous breast reconstruction free flap tranexamic acid
study of safety and efficacy on new peritoneal dialysis solutions

Conditions: End-Stage Renal Disease

Summary: a major challenge of peritoneal dialysis (pd) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (uf) profile. study hypothesis is to evaluate the possibility to formulate pd solutions containing xylitol and l-carnitine as osmotic agents to partially replace glucose.


Eligibility criteria:
inclusion criteria: * age ≥18 years; * diagnosis of esrd treated for at least three month with capd, as stated by the medical staff of the center; * capd treatment with 2.27% of glucose solution for the nocturnal exchange; * stable clinical condition within four weeks before screening period, certified by medical/surgical history, physical examination and laboratory exploration; * hemoglobin level ≥9g/dl; * residual diuresis ≤800ml; * absence of acute peritonitis and/or peritoneal catheter infection (either exit site or subcutaneous tunnel) episodes within three months before selection; * stable peritoneal permeability, as confirmed by a pet between 0.50 and 0.81 during previous three months and at day 0 of the screening period; * total urea kt/v \>1.5 per week at a control during previous three months and at day 0 of the screening period and/or minimal total creatinine clearance of 45 liter/week at a control during previous three months and at day 0 of the screening period; 1- to understand and sign an informed consent form. for patients who will be included in group b, the following criteria must be fulfilled too: * be treated with extraneal (nocturnal exchange bag solution) for at least 1 month * be treated with 2 or 3 diurnal exchange bag solutions (solution bags with 1.36% or 2.27% glucose) and one nocturnal exchange bag solution (extraneal) exclusion criteria: * history of alcohol or drug abuse in the last six months before selection for the study; * androgen therapy in the last six months before selection; * active infections; * history of congestive heart failure stage iii and iv nyha; * history of major cardiovascular events like stroke, acute myocardial infarction, coronary or other arterial revascularization procedures in the last three months before selection; * clinically relevant cardiac arrhythmia; * clinically relevant abnormalities of functional hepatic tests; * therapy with l-carnitine or its derivatives in the last three months before selection; * pregnancy, lactating women or female subjects of childbearing potential who do not use an effective method of contraception; * presence of relevant chronic medical conditions that could suggest exclusion of patient from the study or could interfere with assessment of study parameters, especially if the life expectation is less then one year; * participation in another clinical study within the past month; * known or supposed allergic reactions to l-carnitine or xylitol.

Keywords: l-carnitine xylitol peritoneal dialysis
evaluation of culture negative severe acute respiratory infection in mexico

Conditions: Severe Acute Respiratory Infection (SARI)

Summary: the purpose of this study is to determine the feasibility of identifying novel etiologic agents associated with sari in patients who have required intubation and in whom, after analysis, a causative agent was not identified by standard microbiologic (culture) and multiplex real-time polymerase chain reaction (pcr) platforms. taking into account that isolation of any pathogens is generally time sensitive, the study will evaluate subjects that are culture negative at the time of consent. not all subjects will actually prove to be culture negative. additionally, the study will compare etiologic agents identified on broncho-alveolar lavage (bal) to etiologic agents identified by routine upper airway testing on all subjects with sari.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * willing to provide informed consent; or a legal representative is willing to sign informed consent; * intubated due to an independent clinical decision by a clinician responsible for the patient's clinical care and not affiliated with the research); * meet who's sari definition (modified) - all of the criteria below: * history of fever, subjective feverishness or measured fever of ≥ 38.0 °c, or hypothermia as defined for systemic inflammatory response syndrome (sirs) (\<36.0 °c ); * cough or other respiratory symptoms, such as rapidly progressing dyspnea; * onset within the last 21 days (as long as the clinical condition is considered acute and due to the severity it requires intubation); and * requiring hospitalization exclusion criteria: * intubated for reasons other than sari (cardiovascular accident, surgery); * known microbiologic diagnosis of sari or respiratory illness: * any contraindication to bal by bronchoscopy as determined by the treating physician * bacterial culture or other microbiologic testing for underlying etiology positive would be excluded; * in women: pregnancy
treatment of insomnia and glucose metabolism

Conditions: Sleep; Insomnia; Insulin Resistance

Summary: available data suggest that obtaining adequate sleep is associated with a better ability of the body to use carbohydrates as a source of energy and a lower risk of developing diabetes. the sleeping pill, eszopiclone (lunesta), has been approved by the food and drug administration for the treatment of people who complain of trouble falling or staying asleep. this study will examine the hypothesis that the use of eszopiclone (lunesta) to improve the sleep of people with insomnia may also improve the use of sugar in their body.

study participants will complete a set of oral and intravenous glucose (sugar) tolerance tests, which will be performed on two separate occasions in random order: once after a week of treatment with eszopiclone (lunesta) and once again after a week of receiving placebo.

Eligibility criteria:
inclusion criteria: * age between 35 and 64 * must have long-standing trouble falling or staying asleep * bmi between 22 and 34 kg/m2 exclusion criteria: * sleep apnea or other sleep disorder other than insomnia * diagnosis of diabetes requiring treatment with pills or insulin * smoking * night or shift work * presence of a medical condition that can disrupt sleep * women only: irregular menstrual periods or pregnancy * use of medications/compounds that can disrupt sleep

Keywords: sleep eszopiclone insulin secretion insulin action glucose tolerance
assessment of cognitive function and exercise capacity in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: no studies in the literature have investigated the simultaneous effects of cognitive function, exercise capacity and arterial stiffness in adult patients with cf. the study aims to compare the cognitive function, exercise capacity, exercise muscle oxygenation, and arterial stiffness of adult patients with cf and healthy subjects.

cystic fibrosis (cf) affects other body systems as well as the respiratory system. patients with cf seem to have reduced exercise capacity, which is a major contributor to mortality rates. changes in lung function, ventilatory dysfunction, and respiratory muscle function potentially contribute to exercise intolerance in cf. both children and adults with cf exhibit neurocognitive dysfunction. arterial stiffness is a predictor of cardiovascular events, including myocardial infarction, heart failure, and mortality. individuals with cf exhibit an increase in arterial stiffness. however, no studies in the literature have investigated cognitive function, exercise capacity, and arterial stiffness coexistence in adult cf patients. the study aims to compare the cognitive function, exercise capacity, exercise muscle oxygenation and arterial stiffness in adult patients with cf and healthy subjects. additionally, it will determine the relationship between cognitive function and arterial stiffness with exercise capacity and muscle oxygenation during exercise in adult patients with cf.

Eligibility criteria:
inclusion criteria: * having been diagnosed with cystic fibrosis * being 18 years old and older * clinically stable condition * able to cooperate with the tests performed * volunteered to participate in the study for the control group: * being 18 years old and older * volunteered to participate in the study exclusion criteria: * history of hospitalization or exacerbation in the last month. * chronic respiratory failure and long-term use of oxygen therapy * using noninvasive mechanical ventilator therapy * indication for lung transplantation * who had a lung transplant * forced expiratory volume in the first second (fev1) value 30% and below * cf-related diabetes * chronic liver disease * allergic bronchopulmonary aspergillosis * systemic steroid use * history of diagnosed orthopedic or musculoskeletal problems affecting mobility * cardiovascular instability * serious psychiatric illness for the control group: * known chronic or systemic disease * who did not volunteer to participate in the study

Keywords: cystic fibrosis exercise test cognitive impairment arterial stiffness
basic documentation of adalimumab (humira) in patients with ankylosing spondylitis (as)

Conditions: Ankylosing Spondylitis

Summary: the research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in germany.

this was a postmarketing observational study (pmos) for participants with insufficiently controlled, moderate to severe, active as who were eligible for adalimumab therapy. participants started treatment with adalimumab under normal clinical settings in germany. enrolled participants were followed during adalimumab therapy . participants were assessed during regular clinic visits for up to 24 months and 359 clinicians (rheumatologists/orthopedists/general practitioners/internist) participated in the study. since this was an observational trial, not all doctors followed the stated age limitations and some participants under the age of 18 were enrolled.

Eligibility criteria:
inclusion criteria: 1. participants with active, as for at least 4 weeks (basdai greater than or equal to 4). 2. participants who failed treatment with two non-steroidal anti-inflammatory drugs (nsaids). 3. no contraindications for anti-tumor necrosis factors (tnf) therapy. exclusion criteria: 1. participants who do not meet the above listed inclusion criteria.

Keywords: daily practice humira efficacy safety ankylosing spondylitis
refractory status epilepticus treatment: quality and efficacy of coma induction

Conditions: Status Epilepticus; Refractory Status Epilepticus

Summary: this study is to investigate the effects of different treatment characteristics regarding the use of intravenous anesthetic drugs (ivads) as a rescue treatment for refractory status epilepticus (rse) on course and outcome. a retrospective data extraction from the digital medical records, the electroencephalographic and microbiologic database of all consecutive adult patients with status epilepticus (se) admitted to the university hospital basel is undertaken.


Eligibility criteria:
inclusion criteria: * diagnosed se between 2005 and 2019 who have been treated at intensive care units (icus) of the university hospital of basel exclusion criteria: * patients with repetitive epileptic seizures not qualifying for se or rse * patients with documented refusal of the general in-house consent

Keywords: artificial deep coma intravenous anesthetic drugs (ivads) total seizure oppression
impact on quality of life 3 years after diagnosis of prostate cancer

Conditions: Prostatic Neoplasms; Quality of Life

Summary: to study the quality of life of patients with prostate cancer at a distance from their care at a time when they are supposed to have taken a "normal" life and compared to subjects without cancer prostate of the same age.


Eligibility criteria:
- exposed group inclusion criteria: * prostate cancer diagnosed from 1 december 2011 to 31 december 2014 * under 75 and residing in the hérault department at diagnosis * recruited in the epicap study exclusion criteria: * having relapsed in the range * non-exposed group: inclusion criteria: * controls (without prostate cancer) recruited in the epicap study * matched to cases on age (5 years) * residing in the hérault department exclusion criteria: * diagnosis of prostate cancer set in the range